Pharma feed
N
The FDA said Thursday that it has approved three marketing applications from Sun Pharmaceutical, Biocon and HEC Pharm for the first generics of Novartis' Gilenya (fingolimod) to treat relapsing forms of multiple sclerosis (MS) in adults.
N
Bristol-Myers Squibb (NYSE:BMY) declares $0.45/share quarterly dividend, 9.8% increase from prior dividend of $0.41. Forward yield 3.02% Payable Feb. 3; for shareholders of record Jan. 3; ex-div Jan. 2.
N
The FDA approves generic versions of Novartis' (NVS +0.2% ) MS med Gilenya (fingolimod) made by HEC Pharm Co., Ltd., Biocon Limited and Sun Pharmaceutical Industries Limited.
N
A Midwestern drugmaker is creating a new internal oncology research and development group as part of its integration of a biotech company it acquired earlier this year. Indianapolis-based Eli Lilly & Co. said it would create a new organization within the company, Loxo Oncology at Lilly.
Kelly Bayer Rosmarin is the new CEO of Optus, replacing Alan Lew, who will move to the management team of Optus parent Singtel after five years at the helm of the Australian telco. Bayer Rosmarin has been Optus deputy CEO since joining from the Commonwealth Bank in March after missing out on the bank’s CEO opening.
N
Basel, Switzerland, December 06, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba® (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a sales milestone payment to Basilea of USD 7 million.
N
The Johnson & Johnson Medical Devices Companies today announced that DePuy Synthes has launched the SYMPHONY Occipito-Cervico-Thoracic (OCT) System, expanding its offering for the surgical treatment of conditions in the neck and upper back. The SYMPHONY System includes a differentiated offering of instruments and implants designed for stabilization of the spine in patients undergoing Posterior Cervical Fusion surgery.
N
BAYER TO CLOSE FACILITY IN PITTSBURGH AREA, FORMERLY KNOWN AS MOBAY Pittsburgh Post-Gazette reports: Covestro plans to buy a prominent site it occupies along the Parkway West that for 60 years was the North American headquarters of German drug giant Bayer.
N
Judy Chou will go from a multinational company that made everything from aspirin to hemophilia A treatments to a smaller company with multiple drugs in clinical trials.
N
Today, the FDA approved Amgen’s AVSOLA (infliximab-axxq), a biosimilar to Janssen’s REMICADE. AVSOLA has the same approved indications label as its reference product.
N
A DOJ lawyer's email sheds light on why the DOJ found the proposal to be inadequate.
Do you want to link to this External Site and leave Amgen.com? YOU ARE NOW LEAVING AMGEN'S WEB SITE.
N
Mergers and acquisitions abounded in the Valley during 2019, from Amgen Inc.'s $13.4 billion buy of psoriasis drug Otezla to ServiceTitan's purchase of a water treatment software firm. In addition to M&A, the report features real estate transactions, partnerships and executive hirings and firings.
N
Amgen Inc. on Friday announced its biosimilar treatment for rheumatoid arthritis was approved by the Food and Drug Administration. The Thousand Oaks biotech’s Avsola is a biosimilar copy of Remicade, Johnson & Johnson’s blockbuster drug that also treats rheumatoid arthritis.
N
(RTTNews) - The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.
N
Novartis’ blockbuster multiple sclerosis drug Gilenya (fingolimod) may soon face generic competitors in the U.S., following three FDA approvals. Biocon, HEC Pharm and Sun Pharmaceutical all received the agency’s approval for their generic versions of the immunosuppressive drug, which is intended to treat relapsing forms of the chronic, inflammatory autoimmune disease in adult patients.
Job Description More than $50bn of net sales, more than $12bn of net income, 155 countries where our products are sold - these are the underlying numbers of Novartis that need to be managed from a tax and accounting perspective! As our Head Tax Reporting and Tax Accounting, you will lead tax accounting within the Novartis Group and provide functional guidance to the FRA Operations teams.
N
Johnson & Johnson (NYSE:JNJ) may file new claims in a surgical stapler patent case brought by Intuitive Surgical (NSDQ:ISRG) against J&J’s Ethicon unit. The original patent was granted in 2015. Ethicon sued Intuitive in Delaware in 2017, alleging that with the EndoWrist stapler Intuitive developed for its da Vinci robot-assisted surgery platform, Intuitive violates seven Ethicon patents covering its Echelon Flex line of endocutters and staplers.
Our Company New Brunswick, NJ (December 5, 2019) – Johnson & Johnson announced today that Hubert Joly, Executive Chairman of Best Buy Co., Inc, and Mark A. Weinberger, Former EY Global Chairman and CEO, have been appointed to its Board of Directors.